9:00 a.m. Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer. Kamrine Poels*, Department of Biostatistics, Harvard T.H. CHan School of Public Health
Adam J Schoenfeld, Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center
Alex Makhnin, Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center
Yosef Tobi, Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center
Yuli Wang, Oncology Research and Development, Pfizer Inc
Aaron Hata, Massachusetts General Hospital Cancer Center
Scott L Weinrich, Oncology Research and Development, Pfizer Inc
Helena A Yu, Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center
Franziska Michor, The Ludwig Center at Harvard; Center for Cancer Evolution, Dana Farber Cancer Insitute
(1163-92-1421)
11:30 a.m. Image Segmentation via Hypergraph-based MRF Models. Jessica C De Silva*, California State University, Stanislaus
Darcy Brunk, California State University, Stanislaus
Juan Valencia, California State University, Stanislaus
Talita Perciano, Lawrence Berkeley National Laboratory
(1163-68-1022)